Lynne Lederman, PhD | Authors


Can CDK4/6 Inhibitors Be Optimized for Breast Cancer?

February 25, 2021

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

Clinical Trials Are Underway on Novel Approaches to CML-Resistant BCR-ABL1 Inhibitors

November 27, 2020

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

Incorporating Genomics into Lymphoma Classification Can Improve Care

November 21, 2020

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.